Glucagon receptor antagonists

US12208071B2 · kind B2 · utility

Assignee

• Ligand Pharmaceuticals Incorporated · US

Inventors

• Lin Zhi · San Diego, US
• Ian Henderson · Plainsboro, US
• Joseph Kaloko · Durham, US
• Martin Osterhout · Raleigh, US

Key dates

• Filing date: Feb 13, 2019
• Grant date: Jan 28, 2025
• Expiry date: Nov 13, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.